Electrophysiological changes of angiotensin-converting enzyme inhibition after myocardial infarction

J Card Fail. 2000 Jun;6(2):77-9. doi: 10.1016/s1071-9164(00)90007-1.

Abstract

To investigate whether prevention of remodeling would translate into a more stable electrophysiological profile, the investigators randomized 56 patients to treatment with angiotensin-converting enzyme (ACE) inhibition or placebo for 3 months after myocardial infarction. Programmed electrical stimulation revealed no significant differences in inducibility of monomorphic sustained ventricular tachycardia (VT), whereas ventricular fibrillation (VF) tended to be lower in the ACE-inhibitor group. Effective refractory periods were consistently longer, and dispersion of refractoriness was significantly shorter in the ACE-inhibitor group. The investigators conclude that in this small patient group ACE inhibition may mildly add to a more stable electrophysiological profile.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Cardiac Pacing, Artificial
  • Double-Blind Method
  • Electrocardiography / drug effects*
  • Humans
  • Myocardial Infarction / complications
  • Myocardial Infarction / physiopathology*
  • Myocardial Infarction / therapy
  • Perindopril / therapeutic use*
  • Stroke Volume / drug effects
  • Ventricular Dysfunction, Left / etiology
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Dysfunction, Left / therapy
  • Ventricular Remodeling / drug effects

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Perindopril